MicuRx Pharmaceuticals Public
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
Technology:
Small Molecules
Number Of Exists:
N/A
Investment Stage:
N/A
Founded Date:
2007
Headquarters:
Hayward, California, United States
Employee Number:
11-50
Estimated Revenue:
$10M to $50M
Investor Type:
N/A
Funding Status:
Late Stage Venture
Industry:
PharmTech